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Annane D, Sebille V, Bellissant E: Effect of low doses of 
corticosteroids in septic shock patients with or without early 
acute respiratory distress syndrome. Crit Care Med 2006, 
34:22-30 [1]. 
Background 
Experimental evidence suggests that corticosteroids may be 
beneficial in early acute respiratory distress syndrome 
(ARDS). 
Methods 
Objective: To investigate the efficacy of low doses of 
corticosteroids in septic shock patients with or without early 
ARDS by post hoc analysis of a previously completed 
clinical trial. 
Design:  Retrospective analysis of a placebo-controlled, 
randomized, double-blind trial of low doses of 
corticosteroids in septic shock. 
Setting: Nineteen intensive care units in France. 
Subjects:  Among the 300 septic shock patients enrolled, 
we selected those meeting standard criteria for ARDS at 
inclusion. 
Intervention:  Seven-day treatment with 50 mg of 
hydrocortisone every 6 hrs and 50 µg of 9-alpha-
fludrocortisone once a day.  
Measurements and main results: There were 177 patients 
with ARDS (placebo, n = 92; corticosteroids, n = 85) 
including 129 (placebo, n = 67; corticosteroids, n = 62) 
nonresponders and 48 (placebo, n = 25; corticosteroids, n = 
23) responders. In nonresponders, there were 50 deaths 
(75%) in the placebo group and 33 deaths (53%) in the 
steroid group (hazard ratio 0.57, 95% confidence interval 
0.36-0.89, p = .013; relative risk 0.71, 95% confidence 
interval 0.54-0.94, p = .011). The number of days alive and 
off the ventilator was 2.6 +/- 6.6 in the placebo group and 
5.7 +/- 8.6 in the steroid group (p = .006). There was no 
significant difference between groups in responders. There 
was no significant difference between groups in the two 
subsets of patients without ARDS. Adverse events rates 
were similar in the two groups. 
Conclusion 
This post hoc analysis shows that a 7-day treatment with 
low doses of corticosteroids was associated with better 
outcomes in septic shock-associated early ARDS 
nonresponders, but not in responders and not in septic 
shock patients without ARDS. 
Commentary 
It is difficult to imagine a topic that generates a more heated 
debate than that of the role of corticosteroids (steroids) in 
ARDS. First described in 1967 [2,3], ARDS is an acute life 
threatening condition characterized by excessive and 
protracted systemic inflammation. Given their anti-
inflammatory properties, steroids have been evaluated as a 
potential treatment for ARDS using a variety of doses and 
durations and at various time points in the course of ARDS. 
Short courses of high dose steroids in ARDS are not 
beneficial [4,5]. Interest in this therapy was renewed when 
an apparent survival benefit was demonstrated in a single-
center randomized trial of low dose prolonged steroids in 
late ARDS [6].  
In the current study, Annane and colleagues explored the 
effect of seven days of treatment with low dose steroids in 
septic shock patients with or without early ARDS [1]. This 
study was a post hoc subgroup analysis of data obtained 
previously in another completed clinical trial [7]. Among the 
300 subjects enrolled in the original trial, there were 177 
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patients with early ARDS, including 129 non-responders to 
the short cosyntropin stimulation test (steroids, n = 62; 
placebo, n = 67) and 48 responders (steroids, n = 23; 
placebo, n = 25). The steroid-treated and placebo groups 
were well balanced at baseline. Among non-responders with 
early ARDS, 28-day mortality was significantly lower in 
those receiving steroids (53% vs. 75%, p=0.01). There was 
no significant difference between groups in the rates of 
adverse events, such as superinfection, gastrointestinal 
bleeding, or psychiatric disorders. Interestingly, there were 
no differences in clinical outcomes between the steroid and 
placebo groups for the subgroup of early ARDS responders 
or for those without early ARDS, regardless of responder 
status. These results persisted after adjustment for baseline 
cortisol, cortisol response, McCabe class, Logistic Organ 
Dysfunction score, arterial lactates, and PaO2/FiO2 ratios. 
The authors conclude that their findings should be 
confirmed in multicenter trial. 
This was a well-done study and an insightful application of 
existing clinical trial data to inform the “steroids for ARDS” 
debate. An obvious limitation is one inherent in any post hoc 
subgroup analysis: multiple comparisons can lead to 
misleading conclusions. To emphasize the danger of post 
hoc subgroup analysis, one group demonstrated in data 
from a randomized trial that there was a statistically 
significant association between astrological birth sign and 
the effect of aspirin on mortality in acute myocardial 
infarction [8]. Such statistical aberrations are more likely 
when multiple combinations of subgroups are examined, 
especially if the approach is not hypothesis driven. This was 
not the case in the current study. Because this study was 
conducted before publication of the ARDS Network low tidal 
volume trial  [9], the mean ventilator tidal volume in each 
group was 9 mL/kg of observed body weight. Since lower 
tidal volumes reduce inflammation and improve outcome in 
ARDS, it is not known whether steroids would still be 
beneficial when a low tidal volume strategy is utilized. 
This and other recent trials raise several interesting issues. 
In the current study, steroids were of no benefit in septic 
shock patients without ARDS, which might lead one to 
conclude that the benefit of steroids in septic shock [7] is 
due to treatment of ARDS rather than adrenal insufficiency. 
This might explain the failure of the 500 patient multicenter 
CORTICUS trial to show a mortality benefit for steroids in 
patients with septic shock, although other explanations have 
been offered [10]. Supporting the findings of the current 
study, Meduri and colleagues recently reported the results 
of a five-center 91 patient randomized trial of low-dose 
prolonged steroid infusion in early severe ARDS. The 
authors found significantly improved lung function and ICU 
mortality in steroid treated subjects, and a trend toward 
lower hospital morality [11]. Mean tidal volume was not 
reported in this trial, but was likely greater than 6 mL/kg 
since the study was conducted between years 1997 and 
2002. While the authors did assess adrenal function at 
entry, the small size of the trial limited any meaningful 
subgroup analysis by cosyntropin responsiveness. 
Furthermore, the large late crossover rate (control subjects 
received steroids if they failed to improve by study days 7 to 
9) could have biased results in favor of the steroid group, 
given the results of another recent trial which suggested 
harm when steroids were given late in the progression of 
ARDS [12]. This latter trial, in turn, has also been criticized, 
with some suggesting too rapid weaning of steroids or the 
permitted use of neuromuscular blockers might explain the 
failure to find a benefit. 
Recommendation 
As suggested by the authors of the current study [1] as well 
as the more recent Meduri and colleagues study [11], a 
larger randomized controlled trial of low-dose prolonged 
steroids in patients with early ARDS is warranted. Such a 
trial should stratify patients according to cosyntropin 
responsiveness and, perhaps, whether they have shock at 
study entry. Furthermore, close attention must be paid to 
infection surveillance, tight blood glucose control, avoidance 
of neuromuscular blockers, and the use of low tidal volume 
ventilation. 
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